IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for Ide397 Monotherapy in Mtap-Deletion Squamous Non-Small Cell Lung Cancer
IDEAYA Biosciences宣佈爲Mtap缺失鱗狀非小細胞肺癌的Ide397單一療法選擇向前推進的2期擴張劑量
IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for Ide397 Monotherapy in Mtap-Deletion Squamous Non-Small Cell Lung Cancer
IDEAYA Biosciences宣佈爲Mtap缺失鱗狀非小細胞肺癌的Ide397單一療法選擇向前推進的2期擴張劑量
使用瀏覽器的分享功能,分享給你的好友吧